Aumed, a.s., Komořanská 326/63, 143 14 Praha - Modřany, Česká republika

+420 603 587 701 English

AUMED a.s. founded a new company AUMED Immunology a.s.. AUMED, a.s. is the sole shareholder of the newly formed company. The company AUMED Immunology a.s. was founded with the aim of registering and marketing a new medicinal product containing transfer factor as an active medicinal substance in the form of an oral lyophilized tablet. The new medicinal product will be based on the results of own research activities in the field of transfer factors (more detailed information here). The registration plan for a newly developed medicinal product belongs to the long-term business concept and strategy of AUMED, a.s.. You can learn more about the registration process and clinical trials on AUMED Immunology’s own website. (

Research projects of Aumed, a.s. are financed by the European Structural Funds:
Research and development of a new pertussis vaccine
Transfer factor — research and development of a new medical form
Production of diagnostic kit for covid-19 on the lamp principle
TFI Transfer Factor – Medicine

and with financial support from the state budget through the Ministry of Industry and Trade in the TRIO program:
Research and development of a new oral administration of vaccine

European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness

Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s